MedTrace Logo

The Impact of a Novel Infant Formula on Immunity, Gut Health and Growth

NCT06686433 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2026-03-17

No results posted yet for this study

Summary

The goal of this multicenter, double-blind, randomized, controlled trial is to assess the safety and efficacy of a new infant formula on healthy term infants from enrollment to the age of 6 months.

Conditions

  • Healthy Term Infant

Interventions

OTHER

Novel infant formula

Infants are fed with the novel infant formula from the date of enrollment to the age of 6 months.

OTHER

Standard infant formula

Infants are fed with the standard infant formula from the date of enrollment to the age of 6 months.

Sponsors & Collaborators

  • Merieux NutriSciences (China)

    collaborator UNKNOWN

  • BioFortis

    collaborator OTHER

  • Biostime (Guangzhou) Health Products Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
42 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-13
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686433 on ClinicalTrials.gov